Application of mesenchymal stem cells in medicine for treating thin endometrial and intrauterine adhesion
Through the combined treatment of umbilical cord mesenchymal stem cells, amniotic decellularization scaffolds and polysebacterate, the problem of poor efficacy in treating thin endometrium and uterine cavity adhesions in the prior art is solved, and the endometrium is effective Repair and fertility improvement.
Patent Information
- Application Number
- CN202411013648.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing methods of treating thin endometrium and uterine adhesions have poor treatment effects, high recurrence rate, and lack safe and effective clinical treatment plans.
Using a combination of umbilical cord mesenchymal stem cells, amniotic decellularization scaffold and polysebacterate, the umbilical cord mesenchymal stem cells were transplanted at the endometrial injury, and polysebacterate was used to improve cell fusion. Sex and residence time, repair the endometrium and inhibit inflammatory response.
Significantly improve the endometrial thickness and gland count of rats, reduce endometrial fibrosis, reduce inflammatory response, improve the repair effect of endometrium, reduce the risk of recurrence of uterine adhesions, and enhance fertility.
Smart Images

Figure BDA0004965220430000101 
Figure BDA0004965220430000111
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of stem cell therapy, and more specifically to the application of mesenchymal stem cells in a drug for treating thin endometrium and intrauterine adhesion. Background Art
[0002] Thin endometrium is a common female reproductive disease. When an ultrasound examination is performed, if the thickness of the endometrium cannot reach 7mm, it can be judged as thin endometrium. The most common cause of thin endometrium is intrauterine adhesion caused by surgery. The damage to the endometrium will cause fibrous connections to form between the endometrium during the repair process. More than 90% of intrauterine adhesions are the result of curettage after abortion, which manifests as scanty menstruation and failed embryo implantation. It can also lead to recurrent miscarriage, premature birth, placental adhesions, etc. Similarly, various intrauterine operations including electroresection and hysteroplasty such as mediastinum and bicornuate uterus may cause intrauterine adhesions, leading to thinning of the endometrium.
[0003] Existing treatment methods are limited, with poor treatment effects and high recurrence rates. Clinical treatment measures are mainly based on stimulating endometrial regeneration after adhesion lysis and preventing and treating postoperative re-adhesion, including estrogen therapy, intrauterine balloons, placement of absorbable anti-adhesion materials, amniotic membrane intrauterine transplantation, etc. Estrogen can stimulate endometrial regeneration, accelerate epithelialization of exposed areas, cover uterine wounds, and prevent the formation of new adhesions. Therefore, the combined use of estrogen after adhesion lysis has become the main treatment method and is recognized as the best treatment option; however, the effective rate after treatment is less than 30%, and the recurrence rate exceeds 23.5%. Therefore, the research and development of safe and effective new clinical treatment options has always been a hot and difficult issue in this field.
[0004] Mesenchymal stem cells (MSCs) are a type of adult stem cells with the potential for self-replication and multidirectional differentiation, and they play a very wide role in the field of regenerative medicine. MSCs have the advantages of multidirectional differentiation potential, anti-inflammatory, homing ability, low immunogenicity, wide sources, easy isolation, culture and expansion, and no ethical restrictions, making them an ideal cell source for regenerative medicine. In recent years, preliminary research results at home and abroad have shown that MSCs can repair damaged endometrium, improve its function, and restore some fertility, providing a new treatment strategy for the treatment of intrauterine adhesions.
[0005] In recent years, preliminary research results at home and abroad have shown that mesenchymal stem cells can repair damaged endometrium, improve its function, and restore some fertility. Mesenchymal stem cells from different sources are heterogeneous, with different effects and different degrees of advancement. In order to develop more applications of mesenchymal stem cells in cervical adhesions, it is necessary to verify the effects of different mesenchymal stem cells in animal models, so that stem cell applications can be further promoted to the clinic and stem cell drugs with therapeutic effects can be prepared.
[0006] Therefore, how to provide a new source of mesenchymal stem cells for use in the treatment of thin endometrium and intrauterine adhesions is an urgent problem to be solved by those skilled in the art. Summary of the invention
[0007] In view of this, the present invention provides an application of mesenchymal stem cells in a drug for treating thin endometrium and intrauterine adhesions.
[0008] In order to achieve the above object, the present invention adopts the following technical solution:
[0009] The invention discloses an application of mesenchymal stem cells in a medicine for treating thin endometrium and intrauterine adhesion. The mesenchymal stem cells are umbilical cord mesenchymal stem cells, and the medicine further comprises a sheep decellularized scaffold and polyglyceryl sebacate.
[0010] Furthermore, the method for preparing umbilical cord mesenchymal stem cells comprises the following steps:
[0011] (1) Cleaning: Under sterile conditions, collect the umbilical cord and rinse it 3-5 times with sterile saline to remove impurities on the surface of the umbilical cord and obtain a clean umbilical cord;
[0012] (2) Processing: After the clean umbilical cord is processed, it is cut into small pieces of umbilical cord tissue with a diameter of 4-6 mm, filtered through a 300-400 mesh filter, rinsed with physiological saline, and the small pieces of tissue are transferred to a 100-200 mL sterile container for later use;
[0013] (3) Digestion: Add 2-3 times the volume of the mixed enzyme solution as small as the volume of the umbilical cord tissue to the above sterile container, mix well, place in a 37-42°C water bath, shake and digest for 30-50 min, aspirate the supernatant of the digestion product, and add 10-20 mL of DMEM medium containing 15 mg / L 10% FBS, 100 U / mL penicillin and 100 μg / mL streptomycin to stop digestion and obtain digestion solution;
[0014] (4) Filtration: Filter the digestion solution through a 100-200 mesh sterilization filter to remove the umbilical cord tissue pieces and obtain a filtrate containing umbilical cord tissue mesenchymal stem cells;
[0015] (5) Cultivation: After the filtrate is centrifuged, the supernatant is removed and the resulting cell pellet is washed 3-5 times with a 70-80% ethanol solution by volume, placed in a cell culture medium, and cultured in an incubator at 35-38° C. and 5-10% CO 2 saturated humidity. The cell culture medium is replaced every 60-80 hours to obtain umbilical cord mesenchymal stem cells.
[0016] Furthermore, in step (2), the processing of the umbilical cord includes: longitudinally cutting the ex vivo umbilical cord, removing the veins and arteries and the surrounding tissues close to the blood vessels, flattening the remaining tissue with the inner side of the umbilical cord facing upward, and removing the gelatinous part of the inner side of the umbilical cord until a tissue sheet with a thickness of 0.08-0.15 mm remains.
[0017] Furthermore, in step (3), the mixed enzyme solution contains 1-2 mg / mL collagenase III and 2-3 mg / mL pancreatin.
[0018] Furthermore, in step (5), the removal of supernatant from the cell filtrate includes two centrifugation steps; first, the filtrate is centrifuged at 2000-2300 rpm for 7-9 minutes to remove the supernatant; then, 30-50 mL of DMEM culture medium is added for washing 1-3 times, and the supernatant is removed by centrifugation at 2000-2300 rpm for 3-5 minutes.
[0019] Furthermore, in step (5), the cell culture medium is a D-MEM / F12 culture medium containing 20% fetal bovine serum at a volume concentration of 20-30 mg / L and 5-15 ng / mL of EGF.
[0020] Furthermore, in step (5), the concentration of the umbilical cord mesenchymal stem cells is 1.5 to 3×10 6 Pieces / mL.
[0021] As an inventive concept identical to the above technical solution, the present invention also requests protection for the use of the above umbilical cord mesenchymal stem cells in combination with amniotic membrane decellularized scaffold and polyglycerol sebacate in the preparation of a drug delivery system for treating thin endometrium and intrauterine adhesions.
[0022] As an inventive concept identical to the above-mentioned technical solution, the present invention also requests protection for a cell preparation for treating thin endometrium and intrauterine adhesions, wherein the cell preparation comprises umbilical cord mesenchymal stem cells, amniotic membrane decellularized scaffold, polysebacic acid glycerol and a pharmaceutically acceptable carrier; the mass-to-volume ratio is (5-10) mL: (2-4) mL: (1-3) g: (10-20) mL; and the pharmaceutically acceptable carrier comprises phosphate buffer and / or physiological saline.
[0023] As an inventive concept identical to the above technical solution, the present invention also requests protection for a method for preparing the above cell preparation, wherein the umbilical cord mesenchymal stem cells, amniotic membrane decellularized scaffold, and polyglycerol sebacate are transferred to a centrifuge tube and mixed according to the above volume ratio, centrifuged at 500-800 rpm for 5-10 min, the supernatant is discarded, and a saline solution in a corresponding volume ratio is added to resuspend the cells to obtain a cell preparation.
[0024] It can be seen from the above technical scheme that, compared with the prior art, the present invention discloses an application of mesenchymal stem cells in drugs for treating thin endometrium and intrauterine adhesions, with beneficial effects: the present invention uses umbilical cord mesenchymal stem cells, amniotic membrane decellularized scaffolds and polyglyceryl sebacate in combination, and loads umbilical cord mesenchymal stem cells on an amniotic membrane decellularized scaffold containing polyglyceryl sebacate and transplants them into the uterine cavity with endometrial damage, which can effectively improve the thickness of the rat endometrium, the number of glands and the level of endometrial fibrosis, thereby improving and repairing thin endometrium; and, the treatment method of stem cells + amniotic membrane decellularized scaffold + polyglyceryl sebacate of the present invention can also effectively reduce the release of inflammatory factors in the rat model of intrauterine adhesions, inhibit the proliferation of fibroblasts, reduce inflammatory reactions, play an anti-endometrial fibrosis role, and promote endometrial repair, thereby preventing and treating intrauterine adhesions.
[0025] The present invention combines the advantages of umbilical cord mesenchymal stem cells, amniotic membrane decellularized scaffolds and polyglyceryl sebacate, and utilizes polyglyceryl sebacate to improve the fusion of umbilical cord mesenchymal stem cells and amniotic membrane decellularized scaffolds, thereby increasing the residence time of both in the uterus, so as to better repair the endometrium, thereby achieving the purpose of 1+1+1>3, and providing a new theoretical basis for the treatment of patients with damaged endometrium in clinical practice. DETAILED DESCRIPTION
[0026] The following will be described clearly and completely in conjunction with the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0027] Example 1
[0028] The preparation of umbilical cord mesenchymal stem cells comprises the following steps:
[0029] (1) Cleaning: Under sterile conditions, collect the umbilical cord and rinse it three times with sterile saline to remove impurities on the surface of the umbilical cord to obtain a clean umbilical cord;
[0030] (2) Processing: Cut the ex vivo umbilical cord longitudinally, remove the veins and arteries and the surrounding tissues close to the blood vessels, flatten the remaining tissue with the inner side of the umbilical cord facing up, remove the gelatinous part of the inner side of the umbilical cord until only a tissue piece of about 0.1 mm thickness remains, then cut it into small pieces of umbilical cord tissue with a diameter of 4 mm, filter it with a 300-mesh filter, rinse with physiological saline, and transfer the tissue pieces to a 100-mL sterile container for later use;
[0031] (3) Digestion: Add a mixed enzyme solution containing 1 mg / mL collagenase III and 3 mg / mL pancreatin in an amount twice the volume of the umbilical cord tissue piece to the above sterile container, mix well, and place in a 37°C water bath for shaking digestion for 30 min. Then, aspirate the supernatant of the digestion product and add 15 mL of DMEM medium containing 15 mg / L 10% FBS, 100 U / mL penicillin, and 100 μg / mL streptomycin to stop digestion and obtain a digestion solution;
[0032] (4) Filtration: Filter the digestion solution through a 100-mesh sterile filter to remove the umbilical cord tissue pieces and obtain a filtrate containing umbilical cord tissue mesenchymal stem cells;
[0033] (5) Cultivation: First, the filtrate was centrifuged at 2000 rpm for 9 min, and the supernatant was removed. Then, 30 mL of DMEM medium was added for washing once, and the mixture was centrifuged at 2300 rpm for 3 min. The supernatant was removed, and the resulting cell pellet was washed three times with 70% ethanol solution by volume, and placed in D-MEM / F12 cell culture medium containing 20 mg / L of 20% fetal bovine serum and 15 ng / mL of EGF, and cultured in an incubator at 37°C and 5% CO2 saturated humidity. The cell culture medium was changed every 72 h to obtain a cell culture medium with a concentration of 1.5×10 6 Umbilical cord mesenchymal stem cells per mL.
[0034] Example 2
[0035] The preparation of umbilical cord mesenchymal stem cells comprises the following steps:
[0036] (1) Cleaning: Under sterile conditions, collect the umbilical cord and rinse it four times with sterile saline to remove impurities on the surface of the umbilical cord to obtain a clean umbilical cord;
[0037] (2) Processing: The ex vivo umbilical cord was cut longitudinally, and the veins and arteries as well as the surrounding tissues close to the blood vessels were removed. The remaining tissue was flattened with the inner side of the umbilical cord facing upwards, and the gelatinous part of the inner side of the umbilical cord was removed until only a tissue piece with a thickness of 0.08-0.15 mm remained. The piece was then cut into small pieces of umbilical cord tissue with a diameter of 5 mm. After filtering with a 400-mesh filter, the pieces were rinsed with physiological saline, and the tissue pieces were transferred to a 150-mL sterile container for later use;
[0038] (3) Digestion: Add 3 times the volume of a mixed enzyme solution containing 2 mg / mL collagenase III and 2 mg / mL pancreatin to the above sterile container, mix well, and place in a 39°C water bath for shaking digestion for 40 min. Then, aspirate the supernatant of the digestion product and add 10 mL of DMEM medium containing 15 mg / L 10% FBS, 100 U / mL penicillin, and 100 μg / mL streptomycin to stop digestion and obtain a digestion solution;
[0039] (4) Filtration: Filter the digestion solution through a 200-mesh sterile filter to remove the umbilical cord tissue pieces and obtain a filtrate containing umbilical cord tissue mesenchymal stem cells;
[0040] (5) Cultivation: First, the filtrate was centrifuged at 2300 rpm for 7 min, and the supernatant was removed. Then, 50 mL of DMEM medium was added to wash three times, and the mixture was centrifuged at 2150 rpm for 4 min. The supernatant was removed, and the resulting cell pellet was washed four times with 80% ethanol solution by volume, and placed in D-MEM / F12 cell culture medium containing 25 mg / L of 20% fetal bovine serum and 10 ng / mL of EGF. The mixture was cultured at 38°C in an incubator with 10% CO2 saturated humidity, and the medium was changed every 60 h. A cell pellet with a concentration of 2.3×10 6 Umbilical cord mesenchymal stem cells per mL.
[0041] Example 3
[0042] The preparation of umbilical cord mesenchymal stem cells comprises the following steps:
[0043] (1) Cleaning: Under sterile conditions, collect the umbilical cord and rinse it five times with sterile saline to remove impurities on the surface of the umbilical cord and obtain a clean umbilical cord;
[0044] (2) Processing: Cut the ex vivo umbilical cord longitudinally, remove the veins and arteries and the surrounding tissues close to the blood vessels, flatten the remaining tissue with the inner side of the umbilical cord facing up, remove the gelatinous part of the inner side of the umbilical cord until only 0.08-0.015 mm thick tissue pieces remain, then cut them into small pieces of umbilical cord tissue with a diameter of 6 mm, filter them with a 350-mesh filter, rinse with physiological saline, and transfer the tissue pieces to a 200-mL sterile container for later use;
[0045] (3) Digestion: Add 2.5 times the volume of a mixed enzyme solution containing 1.5 mg / mL collagenase III and 2.5 mg / mL pancreatin to the above sterile container, mix well, place in a 42°C water bath for shaking digestion for 30 min, aspirate the supernatant of the digestion product, add 20 mL of DMEM medium containing 15 mg / L 10% FBS, 100 U / mL penicillin and 100 μg / mL streptomycin, stop digestion, and obtain digestion solution;
[0046] (4) Filtration: Filter the digestion solution through a 150-mesh sterile filter to remove the umbilical cord tissue pieces and obtain a filtrate containing umbilical cord tissue mesenchymal stem cells;
[0047] (5) Cultivation: First, the filtrate was centrifuged at 2150 rpm for 8 min, and the supernatant was removed. Then, 40 mL of DMEM medium was added to wash twice, and the mixture was centrifuged at 2000 rpm for 5 min. The supernatant was removed, and the resulting cell pellet was washed three times with 75% ethanol solution by volume, and placed in D-MEM / F12 cell culture medium containing 30 mg / L of 20% fetal bovine serum and 5 ng / mL of EGF. The mixture was cultured in an incubator at 35°C and 8% CO2 saturated humidity. The medium was changed every 80 h to obtain a cell culture medium with a concentration of 3×10 6 Umbilical cord mesenchymal stem cells per mL.
[0048] Example 4 Subculture of umbilical cord mesenchymal stem cells
[0049] The umbilical cord mesenchymal stem cells obtained in Examples 1-3 were observed under a microscope. When the fusion rate of the umbilical cord mesenchymal stem cells reached 75% under a microscope, the cells could be passaged and washed three times with a sterile PBS solution. Then, 2 mL of PBS solution was added to the cell culture bottle, followed by addition of 2 mL of 0.05-0.1% trypsin solution, and digestion was carried out in a 37° C., 5% CO2 incubator for 1.5 min. When the morphology of the umbilical cord mesenchymal stem cells was observed under a microscope to change from long spindle cells to round cells, 5 mL of termination medium was added to prevent further digestion. The digested cell suspension was transferred to a sterile centrifuge tube, centrifuged at 500 rpm for 5 min, the supernatant was poured off, the cell precipitate was blown and mixed with a complete medium, and then evenly seeded in a new culture bottle, and continued to be cultured in a 37° C., 5% CO2 incubator. The above passage operation was repeated to pass down and purify the umbilical cord mesenchymal stem cells until P5.
[0050] Example 5: Effectiveness test of umbilical cord mesenchymal stem cells in treating thin endometrium
[0051] (1) Establishment of a thin uterus model in SD rats
[0052] Fasting for 12 hours before surgery, intraperitoneal injection of 3-5% sodium pentobarbital for anesthesia; fixation, skin preparation, routine disinfection, and draping; open the abdomen, explore and separate the uterus; the syringe needle enters the uterine cavity and keeps it parallel to the longitudinal axis of the uterus, and slowly injects anhydrous ethanol to keep the uterine cavity filled. After 5 minutes (dosage 0.5mL), the anhydrous ethanol in the uterine cavity is extracted, the needle is fixed, and the uterine cavity is flushed 1 to 2 times with a syringe containing 0.9% sodium chloride solution, and the needle and syringe are removed; the other side of the uterus is treated in the same way; the abdominal cavity is flushed with 0.9% sodium chloride solution and dried with sterile gauze, and the uterus is restored to the anatomical position and the abdomen is closed layer by layer. After postoperative disinfection, sodium penicillin for injection (0.5g per rat) is applied to the surgical site, and the rat is kept warm before waking up. Penicillin is injected intramuscularly for 3 consecutive days after surgery to prevent infection.
[0053] (2) Experimental groups and treatments
[0054] Fifty SD female rats were divided into a control group, a model group, a stem cell group (Example 3), a stem cell + scaffold group (volume ratio of umbilical cord mesenchymal stem cells: amniotic membrane decellularization = 5 mL: 2 mL), and a stem cell + scaffold + polysebacylglycerol group (mass volume ratio of umbilical cord mesenchymal stem cells: amniotic membrane decellularization: polysebacylglycerol = 5 mL: 2 mL: 1 g), with 10 rats in each group. The changes in the estrous cycle of the rats were observed. The model group, stem cell group, stem cell + scaffold group, and stem cell + scaffold + polysebacylglycerol group were modeled during the estrus period.
[0055] Drug treatment: The stem cell group, stem cell + scaffold group, and stem cell + scaffold + polysebacylglycerol group were given 5 mL / kg oral gavage daily; the model group and the control group were given an equal amount of 0.9% sodium chloride solution by oral gavage daily. After continuous drug administration for 12 days, blood was collected from the abdominal aorta during the estrus period after anesthesia, and the serum was separated and stored at -20°C for testing.
[0056] (3) Changes in rat uterine wet weight and uterine organ coefficient after different drug treatments
[0057] The rats were cut open layer by layer to enter the abdominal cavity. The "V"-shaped uterus was found behind the bladder. The ovaries and fallopian tubes on both sides were peeled off. A transverse incision was made 7 mm below the confluence of the cervix on both sides. The uterus was quickly separated and the wet weight of the uterus was weighed. The organ coefficient (wet weight of uterus / body weight) was calculated. The middle 1 / 3 of the uterus on one side was cut off and frozen in a -80℃ refrigerator for examination. The measurement results are shown in Table 1.
[0058] Table 1 Changes in rat uterine wet weight and uterine organ coefficient after different drug treatments
[0059] Group Uterine wet weight (g) Uterine organ index (%) Control group 0.72 0.238 Model Group 0.47 0.179 Stem Cell Group 0.53 0.191 Stem cell + scaffold group 0.65 0.214 Stem cell + scaffold + polyglycerol sebacate group 0.74 0.235
[0060] As shown in Table 1, the wet weight of the uterus and the organ coefficient of the rats in the model group were significantly reduced, which was significantly different from that in the control group; although the stem cell group and the stem cell + scaffold group had a significant effect on uterine weight gain and the organ coefficient also increased, the increase trend was significantly lower than that of the stem cell + scaffold + polysebacic acid glycerol combined administration group.
[0061] (4) Changes in endometrial thickness of rats after different drug treatments
[0062] The endometrial thickness, gland number and endometrial fibrosis ratio of rats after HE staining were observed under K-Viewer digital slice reading software; the endometrial thickness is the vertical distance between the junction of the endometrial myometrium and the uterine cavity. Six slices were randomly selected from each group, and each slice was randomly selected from four directions of up, down, left and right for measurement under a 40× field of view to calculate the endometrial thickness. At the same time, 5 fields of view were selected from each slice for gland counting, and the average value was taken. The measurement results are shown in Table 2.
[0063] Table 2 Changes in endometrial thickness in rats after different drug treatments
[0064]
[0065] As shown in Table 2, the endometrial thickness and the number of glands in the model group were smaller than those in the control group, but the proportion of uterine fibrosis was significantly higher than that in the control group; while the endometrial thickness and the number of glands in the stem cell group, stem cell + scaffold group and stem cell + scaffold + polyglycerol sebacate group were greater than those in the model group after treatment, and the proportion of endometrial fibrosis was significantly lower than that in the model group; and the effect of the stem cell + scaffold + polyglycerol sebacate group after treatment was more significant.
[0066] Example 6: Effectiveness test of umbilical cord mesenchymal stem cells in treating intrauterine adhesions
[0067] (1) Establishment of rat intrauterine adhesion model
[0068] Mature female Sprague-Dawley rats (220-250 g) aged 6-8 weeks were selected and observed by vaginal smear method during the estrous cycle of the rats. In the diestrus period, the rat model of intrauterine adhesion (IUA) was established with reference to the research method of Desheng Kong et al.
[0069] (2) Experimental groups and treatments
[0070] Fifty rats were randomly divided into five groups: a sham operation group, which did not receive any treatment and underwent laparotomy; an IUA model group, which induced intrauterine adhesion in rats, underwent laparotomy again 2 weeks after modeling, and injected 0.2 mL of PBS into each of the two uterine horns; a stem cell treatment group, a stem cell + scaffold treatment group, and a stem cell + scaffold + polysebacylglycerol treatment group, which underwent laparotomy again 2 weeks after modeling, and injected the drug (100 μg dissolved in 0.2 mL PBS) into both uterine horns; 25 rats (n=5 in each group) were killed during the estrus period 4 weeks after treatment, and uterine tissues were collected for measurement.
[0071] (3) Changes of inflammatory indicators in rat serum after different drug treatments
[0072] According to the instructions of the ELISA kit, the levels of inflammatory factors such as TNF-α, IL-6 and TGF-β1 in the serum of rats in each group were detected. The results are shown in Table 3.
[0073] Table 3 The levels of TNF-α, IL-6 and TGF-β1 in rat serum after different drug treatments
[0074]
[0075] As shown in Table 3, compared with the normal group, the expression of serum TNF-a, IL-6 and TGF-β1 in the model group was significantly increased; compared with the model group, the expression of serum TNF-a, IL-6 and TGF-β1 in the stem cell group and stem cell + scaffold group was significantly reduced, but the reduction level was significantly lower than that in the stem cell + scaffold + sebacic acid glyceride group. This shows that the treatment of stem cell + scaffold + sebacic acid glyceride group can effectively reduce the release of inflammatory factors in rats with intrauterine adhesion model, inhibit the proliferation of fibroblasts, and play an anti-inflammatory and tissue repair regulating role.
[0076] (4) Effects of different drug treatments on the fertility of rats with intrauterine adhesion model
[0077] The function of the regenerated uterine horn was evaluated by testing whether it could accept fertilized eggs and support embryonic development to late pregnancy. Eight weeks after treatment, the control group, model group, stem cell group, stem cell + scaffold group, and stem cell + scaffold + glyceryl sebacate group were mated with male rats; the date of vaginal blockage was considered to be day 0 of pregnancy, and the rats were euthanized on day 15 of pregnancy to check whether the uterine horn had embryos. The results are shown in Table 4.
[0078] Table 4 Number of embryo implantation in rats in different drug administration groups
[0079] Group Number of embryo implantation Sham operation group 10.55 Model Group 2.45 Stem Cell Group 4.33 Stem cell + scaffold group 6.09 Stem cell + scaffold + polyglycerol sebacate group 8.78
[0080] Since intrauterine adhesions can lead to embryo implantation failure or reduce the embryo implantation rate, in order to detect the effect of umbilical cord mesenchymal stem cells on endometrial repair, the embryo implantation efficiency of rats in different groups was observed. The results are shown in Table 4. Compared with the normal group rats, the number of embryo implantation in the model group rats was significantly reduced; and compared with the model group, the number of embryo implantation in the stem cell group and the stem cell + scaffold group rats increased, but the increase level was significantly lower than that in the stem cell + scaffold + sebacate group. It can be seen that after the present invention uses the stem cell + scaffold + sebacate group for treatment, it has a regenerative repair effect on the damaged endometrium, and can also improve fertility and increase the pregnancy rate.
[0081] The various embodiments in this specification are described in a progressive manner, and each embodiment focuses on the differences from other embodiments. The same or similar parts between the various embodiments can be referenced to each other.
[0082] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.
Claims
1. An application of mesenchymal stem cells in a drug for treating thin endometrium and intrauterine adhesions, characterized in that: The mesenchymal stem cells are umbilical cord mesenchymal stem cells; and the medicine further comprises amniotic membrane decellularized scaffold and polyglyceryl sebacate.
2. The use according to claim 1, characterized in that: The method for preparing umbilical cord mesenchymal stem cells comprises the following steps: (1) Cleaning: Under sterile conditions, collect the umbilical cord and rinse it 3-5 times with sterile saline to remove impurities on the surface of the umbilical cord and obtain a clean umbilical cord; (2) Processing: After the clean umbilical cord is processed, it is cut into small pieces of umbilical cord tissue with a diameter of 4-6 mm, filtered through a 300-400 mesh filter, rinsed with physiological saline, and the small pieces of tissue are transferred to a 100-200 mL sterile container for later use; (3) Digestion: Add 2-3 times the volume of the mixed enzyme solution of the umbilical cord tissue piece to the above sterile container, mix well, place in a 37-42°C water bath, shake and digest for 30-50 min, aspirate the supernatant of the digestion product, and add 10-20 mL of DMEM medium containing 15 mg / L 10% FBS, 100 U / mL penicillin and 100 μg / mL streptomycin to stop digestion and obtain digestion solution; (4) Filtration: Filter the digestion solution through a 100-200 mesh sterilization filter to remove the umbilical cord tissue pieces and obtain a filtrate containing umbilical cord tissue mesenchymal stem cells; (5) Cultivation: After the filtrate is centrifuged, the supernatant is removed and the resulting cell pellet is washed 3-5 times with a 70-80% ethanol solution by volume, placed in a cell culture medium, and cultured in an incubator at 35-38° C. and 5-10% CO 2 saturated humidity. The cell culture medium is replaced every 60-80 hours to obtain umbilical cord mesenchymal stem cells.
3. The use according to any one of claims 1 or 2, characterized in that: In step (2), the processing of the umbilical cord includes: longitudinally cutting the ex vivo umbilical cord, removing the veins and arteries and the surrounding tissues close to the blood vessels, flattening the remaining tissue with the inner side of the umbilical cord facing upward, and removing the gelatinous part of the inner side of the umbilical cord until a tissue sheet with a thickness of 0.08-0.15 mm remains.
4. The use according to any one of claims 1 or 2, characterized in that: In step (3), the mixed enzyme solution contains 1-2 mg / mL collagenase and 2-3 mg / mL pancreatin.
5. The use according to any one of claims 1 or 2, characterized in that: In step (5), the cell filtrate removal of supernatant includes two centrifugation steps: first, the filtrate is centrifuged at 2000-2300 rpm for 7-9 minutes to remove the supernatant; then, 30-50 mL of DMEM culture medium is added to wash 1-3 times, and the cell filtrate is centrifuged at 2000-2300 rpm for 3-5 minutes to remove the supernatant.
6. The use according to any one of claims 1 or 2, characterized in that: In step (5), the cell culture medium is a D-MEM / F12 culture medium containing 20% fetal bovine serum at a volume concentration of 20-30 mg / L and 5-15 ng / mL EGF.
7. The use according to any one of claims 1 or 2, characterized in that: In step (5), the concentration of the umbilical cord mesenchymal stem cells is 1.5-3×10 6 Pieces / mL.
8. Application of umbilical cord mesenchymal stem cells in combination with amniotic membrane decellularized scaffold and polyglycerol sebacate in the preparation of a drug delivery system for the treatment of thin endometrium and intrauterine adhesions.
9. A cell preparation for treating thin endometrium and intrauterine adhesions, characterized in that: The cell preparation includes umbilical cord mesenchymal stem cells, amniotic membrane decellularized scaffold, polyglyceryl sebacate and a pharmaceutically acceptable carrier; the mass-to-volume ratio is (5-10) mL: (2-4) mL: (1-3) g: (10-20) mL; and the pharmaceutically acceptable carrier includes phosphate buffer and / or physiological saline.
10. The method for preparing a cell preparation according to claim 9, characterized in that: According to the volume ratio of claim 9, umbilical cord mesenchymal stem cells, amniotic membrane decellularized scaffold and polysebacylglycerol are transferred to a centrifuge tube for mixing, centrifuged at 500-800 rpm for 5-10 min, the supernatant is discarded, and saline solution of the corresponding volume ratio is added to resuspend the cells to prepare a cell preparation.
Citation Information
Patent Citations
PGS / BMSCs composite support used for promoting recovery of injured uterus and preparation method thereof
CN107537068A
Application of mesenchymal stem cells in preparation of medicine for treating intrauterine adhesion
CN116870032A
Omentum based scaffold and delivery system
US20150202348A1
Cited By
Application of mesenchymal stem cells in medicine for treating thin endometrium and uterine cavity adhesion
CN121574247A
Application of a mesenchymal stem cell therapy in the treatment of thin endometrium and intrauterine adhesions
CN121574247B
